Literature DB >> 24841270

Protein binding of rifapentine and its 25-desacetyl metabolite in patients with pulmonary tuberculosis.

Eric F Egelund1, Marc Weiner2, Rajendra P Singh3, Thomas J Prihoda4, Jonathon A L Gelfond5, Hartmut Derendorf1, William R Mac Kenzie6, Charles A Peloquin1.   

Abstract

Rifapentine is highly protein bound in blood, but the free, unbound drug is the microbiologically active fraction. In this exploratory study, we characterized the free plasma fraction of rifapentine in 41 patients with tuberculosis. We found a lower total rifapentine concentration but significantly higher free rifapentine levels in African patients of black race compared to non-Africans. These data support larger pharmacokinetic/pharmacodynamic studies to confirm these findings and assess free rifapentine in relation to microbiological and clinical outcomes.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24841270      PMCID： PMC4136068          DOI： 10.1128/AAC.01730-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG.

Authors:  N Rastogi; K S Goh; M Berchel; A Bryskier
Journal:  J Antimicrob Chemother       Date:  2000-10       Impact factor: 5.790

Review 2.  The extraordinary ligand binding properties of human serum albumin.

Authors:  Mauro Fasano; Stephen Curry; Enzo Terreno; Monica Galliano; Gabriella Fanali; Pasquale Narciso; Stefania Notari; Paolo Ascenzi
Journal:  IUBMB Life       Date:  2005-12       Impact factor: 3.885

3.  Association between serum albumin levels and in-hospital deaths due to tuberculosis.

Authors:  E D Matos; A C Moreira Lemos
Journal:  Int J Tuberc Lung Dis       Date:  2006-12       Impact factor: 2.373

4.  Serum albumin as a prognostic indicator for HIV disease progression.

Authors:  Shruti H Mehta; Jacquie Astemborski; Timothy R Sterling; David L Thomas; David Vlahov
Journal:  AIDS Res Hum Retroviruses       Date:  2006-01       Impact factor: 2.205

Review 5.  Measurement and analysis of unbound drug concentrations.

Authors:  J D Wright; F D Boudinot; M R Ujhelyi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

6.  Binding of rifampicin by human plasma proteins.

Authors:  G Boman; V A Ringberger
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

7.  In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein.

Authors:  J Woo; W Cheung; R Chan; H S Chan; A Cheng; K Chan
Journal:  Clin Biochem       Date:  1996-04       Impact factor: 3.281

8.  Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis.

Authors:  L B Heifets; P J Lindholm-Levy; M A Flory
Journal:  Am Rev Respir Dis       Date:  1990-03

9.  Differences between blacks and whites in plasma protein binding of drugs.

Authors:  J A Johnson; T N Livingston
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

10.  Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy.

Authors:  Marc Weiner; Naomi Bock; Charles A Peloquin; William J Burman; Awal Khan; Andrew Vernon; Zhen Zhao; Stephen Weis; Timothy R Sterling; Katherine Hayden; Stefan Goldberg
Journal:  Am J Respir Crit Care Med       Date:  2004-02-12       Impact factor: 21.405
View more
  8 in total

1.  Physiologically Based Pharmacokinetic Model of Rifapentine and 25-Desacetyl Rifapentine Disposition in Humans.

Authors:  Todd J Zurlinden; Garrett J Eppers; Brad Reisfeld
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

2.  Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients.

Authors:  Roger K Verbeeck; Bonifasius S Singu; Dan Kibuule
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

Review 3.  A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.

Authors:  Russell R Kempker; Wael A Alghamdi; Mohammad H Al-Shaer; Gena Burch; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

4.  Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake.

Authors:  M Masud Parvez; Jin Ah Jung; Ho Jung Shin; Dong Hyun Kim; Jae-Gook Shin
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials.

Authors:  R M Savic; M Weiner; W R MacKenzie; M Engle; W C Whitworth; J L Johnson; P Nsubuga; P Nahid; N V Nguyen; C A Peloquin; K E Dooley; S E Dorman
Journal:  Clin Pharmacol Ther       Date:  2017-03-02       Impact factor: 6.875

6.  A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.

Authors:  Jose Francis; Simbarashe P Zvada; Paolo Denti; Mark Hatherill; Salome Charalambous; Stanley Mungofa; Rodney Dawson; Susan Dorman; Nikhil Gupte; Lubbe Wiesner; Amina Jindani; Thomas S Harrison; Adeniyi Olagunju; Deirdre Egan; Andrew Owen; Helen M McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.938

7.  Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System.

Authors:  Gunavanthi D Boorgula; Laxmi U M R Jakkula; Tawanda Gumbo; Bockgie Jung; Shashikant Srivastava
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

8.  New Paradigm for Translational Modeling to Predict Long-term Tuberculosis Treatment Response.

Authors:  I H Bartelink; N Zhang; R J Keizer; N Strydom; P J Converse; K E Dooley; E L Nuermberger; R M Savic
Journal:  Clin Transl Sci       Date:  2017-05-31       Impact factor: 4.689
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.